Cancer Crosslinks is now one of the most relevant meetings for Norwegian oncologists, with 300 delegates attending this year.
The 9th Cancer Crosslinks meeting took place at Oslo Cancer Cluster Innovation Park January 26. It was a great success, gathering the Norwegian Oncology Community with a record high attendance of 300 delegates. They came to learn from each other.
– We strongly believe in bringing oncology professionals from various fields together, so that they can exchange knowledge and get to know one another. In doing so, Cancer Crosslinks could contribute to developing new cancer treatments, since this requires collaboration across both medical disciplines and country borders, says Ketil Widerberg, general manager at Oslo Cancer Cluster.
The delegates were mainly oncologists and hematologists. These two professions have traditionally had little interaction, and there is a need to exchange knowledge between these two groups. In addition, there were many other researchers in oncology among the participants, as well as participants from biotechnology companies that develop cancer treatment.
Download the presentations
For those of you who missed the event or would like to revisit:
You can download presentations from the meeting here:
- Jerome Galon  : Opening Keynote – Cancer and Inflammation.
Prof. Jérôme Galon, Ph.D., Research Director at INSERM; Leader of the INSERM Integrative Cancer Immunology Laboratory, Cordeliers Research Center, Paris, France
- Seth Coffelt : International Keynote – Inflammation lights the way to metastasis.
Dr. Seth B. Coffelt, Cancer Research UK Beatson Institute, Institute of Cancer Sciences, University of Glasgow,
- JRMarchesi : International Keynote – The gut microbiota, inflammation and cancer
Prof. Julian Marchesi, Imperial College London, UK
- WWierda : International Keynote: Hematological cancers: how individualized can we treat patients today?
Prof. William G. Wierda, M.D., Ph.D.; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
- Anna Schuh : International Keynote: The role of clinical -omics for precision medicine approaches in hematology
Dr. Anna Schuh, Director of Molecular Diagnostics in the Department of Oncology; Honorary Consultant Hematologist at Oxford University Hospitals Trust, UK
- Guttorm Haraldsen: Inflammation Research in Norway – core expertise and collaboration opportunities
Prof. Guttorm Haraldsen, KG Jebsen Inflammation Research Center, Oslo
Cancer and the micro environment
They came to listen to and learn from leading Norwegian and international experts from the US and Europe. One of them was professor Julian Marchesi from Imperial College in London. He gave an exciting talk about the research on cancer, inflammation and the gut microbiota, showing results of how what we eat can affect the gut microbiota and hence cancer development.
Professor Jerome Galon from INSERM Integrative Cancer Immunology Laboratory, Cordeliers Research Center in Paris added to the discussion with a key note talk on the immune micro environment on cancer and a method called Immunoscore .
– Immunoscore is a way to classify cancer patients based on immune parameters . It is then possible to classify patients into high- and low risk groups, says Galon in the podcast Radium.
The best treatment for each patient
Professor William G. Wierda from MD Anderson Cancer Centre was another keynote speaker. As an expert in leukemia, he gave insight to the field of precision medicine within hematological cancers. He raised a debate on the question: how individualized can we treat patients today?
Norwegian projects and approaches were also discussed at the meeting. Professor Guttorm Haraldsen, head of KG Jebsen Inflammation Research Center in Oslo gave an overview of Norwegian research and core expertise in the inflammation area. He highlighted opportunities for collaboration with the oncology field.
Another Norwegian example is a project between Dr. Yngvar Fløisand, Senior Consultant, and Dr. Jorrit Enserink, group leader at Oslo University Hospital. They introduced the screening of samples from patients with Acute Myeloid Leukaemia (ALM), to identify the best treatment for each patient. Finally, there was a panel discussion with leading Norwegian experts on the ways forward from data generation to clinical use.
On the previous evening, the delegates participated in thematic roundtables and meetings between Norwegian and international experts. This provided some insight into possible international collaboration in and across their fields of expertise.
10 years anniversary next year
This 9th Cancer Crosslinks meeting was kindly sponsored by Oslo Cancer Cluster members Bristol-Myers Squibb and AbbVie.
You can look forward to the upcoming Cancer Crosslinks Anniversary Editions: The next Swedish Cancer Crosslinks meeting will be held in Lund, October 25th (the date will be confirmed) this year and the 10th Norwegian edition will be in Oslo Cancer Cluster Innovations Park in January 2018.